KRAS and non-small cell lung carcinoma: The authors conclude that among patients with PD-L1 expression of 50% or greater NSCLC treated with ICI monotherapy, KRAS wild type is associated with worse survival compared with KRAS mutant patients; in contrast, survival did not differ appreciably between patients with KRAS mutant and KRAS wild type status who were treated with chemoimmunotherapy.